LIVER

This study evaluated the subacute toxic effects of Cell Life IQ on liver function and lipid profile following 28-day repeated oral administration. Cell Life IQ is a widely used dietary supplement, but its safety profile during prolonged intake remains unclear. To assess potential toxicity, experimental animals were randomly assigned into four groups: a control group receiving distilled water and three treatment groups administered 20mg/kg( low dose) , 80mg/kg (medium doses) and 600mg/kg (high doses )of Cell Life IQ. At the end of the exposure period, blood samples were collected for biochemical analysis of liver function parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein, and albumin. Lipid profile markers such as total cholesterol, triglycerides, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were also measured. The results showed at high dose there was a significant increase in total and direct bilirubin when compared to other groups. Also there was also increase in AST at the higher dose while ALP and ALT was not significantly unchanged at all groups. There was no significant change in the lipid profile parameters ( triglycerides, HDL, LDL etc) in all the treatment groups when compared to the control groups.

Miracle Seed Ultima® (MSU) is widely used as a natural supplement, yet scientific evidence on its safety profile remains limited. This study therefore evaluated the sub-acute toxicity effects of MSU on liver function and lipid metabolism in male Wistar rats. Twenty rats were randomly assigned to four groups and administered 0 mg/kg (control), 100 mg/kg, 300 mg/kg, and 1000 mg/kg of MSU orally for 28 days. Liver biomarkers including ALT, AST, ALP, total protein, albumin, total bilirubin, and direct bilirubin were analysed, while lipid profile parameters (total cholesterol, triglycerides, HDL, LDL, and VLDL) were assessed.The results showed no statistically significant differences (P > 0.05) in AST, ALP, total bilirubin, direct bilirubin, or albumin levels across all doses. However, ALT increased significantly (P < 0.05) in the 300 mg/kg and 1000 mg/kg groups compared with the control, with mean values of 147.35 ± 12.9ᵃ (control), 135.00 ± 8.7ᵃᵇᵈ (300 mg/kg), and 200.56 ± 22.2ᵃᶜᵉ (1000 mg/kg), indicating a dose-related biochemical change. Total protein decreased significantly in the 100 mg/kg group 4.06 ± 0.1ᵃ (control) and 3.39 ± 0.1ᵇᶜ(100mg/kg), although values remained within physiological ranges. Lipid parameters showed no statistically significant alterations, indicating that the observed slight increase in total cholesterol in Group 3 and reduced triglycerides in Group 2 were not biologically meaningful since they were not statistically supported.Overall, the findings indicate that MSU did not produce broad hepatic or lipid toxicity within the 28-day period. Although ALT increased at higher doses, a single enzyme elevation without corresponding changes in other hepatic markers does not conclusively indicate liver damage. Nevertheless, the dose-dependent rise suggests a potential early biochemical response that warrants further attention. The study highlights the need for additional investigations involving histopathology, oxidative stress markers, and long-term exposure to more conclusively establish the safety profile of MSU